The treatment of rectal cancer currently involves coordinated efforts for combined modality therapy with pre-operative chemoradiation followed by surgical management and additional adjuvant chemotherapy. The landscape of rectal cancer has shifted significantly over the past 30 years. This review aims to track this changing landscape, with a particular focus on current research and future endeavors.
Past Treatment
Prior to the 1980s, patients with rectal cancer were predominantly treated with resection. The surgical technique was not standardized, resulting in inconsistent circumferential and distal margins, and technical difficulty of a low pelvic anastomosis frequently led to the need for a permanent colostomy in many instances. Prior to the understanding of the importance of total mesorectal excision (TME), surgical resection led to significant local failure rates, generally about 30-40 %, and up to 67 % in some series with advanced staged disease. [1] [2] [3] To reduce local failure rates, radiation was added postoperatively with a subsequent decrease in recurrence rates to around 20 %. CRT resulted in a 47 % reduction in the risk of relapse and a 36 % reduction in the risk of cancer-related death. 16 Although use of methyl-CCNU is no longer used, the National Institutes of Health consensus conference endorsed the use of postoperative 5-FU based CRT for patients with stage II or III rectal cancer.
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Present Treatment
Although the addition of postoperative CRT improved outcomes, the rate of local pelvic recurrences remained high, leading to significant morbidity.
Improvements in surgical methods, with TME, were an important advance to reduce the rate of local relapses. 18-20 TME now defines a specific surgical technique that includes sharp dissection to preserve the mesorectal fascia, nerve preservation whenever possible, and attention to avascular tissue planes and maintenance of hemostasis. While some upper rectal tumors may be amenable to a 'tumor-specific' mesorectal excision, mid and distal rectal cancers require a TME. Because of the dramatic reduction in local recurrence rates with TME, it is important to note whether TME was performed when comparing clinical trials. With increasing consensus regarding the benefits of CRT, attention shifted to the timing of therapy:
before or after resection. The use of pre-operative CRT is supported by several randomized trials conducted worldwide. [21] [22] [23] [24] The National Surgical Adjuvant Breast and Bowel Project R-03 (NASBP-R-03) was developed to investigate best timing for the administration of multimodality therapy. 21 In this study, 267 patients were randomly assigned to either received pre-operative CRT (n=130) or postoperative CRT (n=137). Pre-operative treatment utilized weekly bolus 5-FU/leucovorin (Lv) for 6 weeks followed by concurrent CRT using 5-FU/Lv for 5 days during the first and fifth week of radiation (45 Gy with a 5.4 Gy boost), followed by weekly 5-FU/Lv for 6 weeks. The postoperative treatment schedule was identical. Importantly, the pre-operative treatment arm had a statistically improved disease-free survival with a hazard ratio of 0.629 (p=0.011) and a trend in improved overall survival. Consistent with a treatment effect, patients assigned to the pre-operative arm had a lower incidence of node positive disease (p=0.04). Moreover, in the evaluable patients who received pre-operative therapy, 15 % had a pathologic complete response (pCR); and patients who were noted to have a complete response had a lower cumulative incidence of recurrence (0 versus 24.7 %; p=0.04).
However, the low accrual (267 of the planned 900 patients) limited the ability to demonstrate a statistically significant improvement in overall survival. Moreover the lack of standardized surgical techniques further confounded this study and also likely contributed to failure to demonstrate an improvement in local recurrence or sphincter salvage rates in the pre-operative group. 21 Nevertheless, the biologic treatment affect seen by CRT and the improvement in disease-free survival continued to drive research into optimizing pre-operative therapy.
The German Rectal Cancer Study Group (CAO/ARO/AIO-94) provided important data demonstrating the benefits of pre-operative CRT. 22 In this large study, over 800 patients with T3 or T4 rectal cancer were randomized to pre-operative treatment with RT/5-FU followed by surgery versus surgery followed by RT/5-FU. Both treatment arms included an additional four months of 5-FU alone. In contrast to the NSABP R-03, 21 TME was the required surgical management in the German trial. Importantly, there was a statistically significant improvement in local relapse rates in the pre-operative treatment arm (6 versus 13 %), which persisted at 10 years. 25 Moreover, in the pre-operative arm, sphincter preservation was demonstrated for low rectal tumors and fewer treatment-related toxicities were observed. Although long-term follow-up did not demonstrate an improvement in overall survival, these findings led the adoption of pre-operative CRT as a mainstay in the multi-modality management of rectal cancer. 22 A Korean Trial additionally suggested a benefit for a preoperative CRT approach. 23 This single institution study randomized 240 patients to either pre-operative or postoperative capecitabine with RT followed by four cycles of capecitabine or 5-FU. Although publication of the German Study 22 led to the low accrual/early closure in the Korean trial, patients with low-lying tumors treated with pre-operative CRT similarly demonstrated a higher rate of sphincter-sparing surgeries. 23 The delivery of 5-FU varied considerably between the various trials described above. Currently, however, continuous infusion 5-FU has been adapted by most institutions based on the NCCTG 26 and INT-0114 27 trials suggesting that infusional 5-FU has improved efficacy and decreased hematologic toxicities compared to bolus 5-FU regimens. Substitution of oral capecitabine with RT in lieu of infusional 5-FU is also an option. 28, 29 However, because of potential issues of patient compliance, variability in bioavailability/correct dosing, and toxicities, such as hand-foot syndrome, our institutional preference is to utilize infusional 5FU whenever possible.
The dose of pelvic radiotherapy has traditionally ranged between 45-54 Gy in most of the prospective studies, many of which were performed prior to the widespread availability of modern 3D conformal treatment planning. There may also be a role for increasing the overall dose of radiotherapy in order to increase the likelihood of obtaining a pCR. 30 Modern radiation techniques continue to improve on minimizing the toxicities of conventional fractionated radiation therapy with 5FU- Smaller trials using short-course radiation also suggest equivalence to conventional radiation (Polish and Trans-Tasman Radiation Oncology Group [TROG] trials). 33, 34 However, at the present time, most US centers prefer conventional fractionation.
Future
While pre-operative CRT is the current recommended care for most patients with T3 or T4 rectal cancers, research continues to evaluate methods to optimize therapy. Improvement in overall survival remains the gold standard to judge a new therapy superior to the current standard.
However such trials often require large numbers and lengthy follow-up. potential benefit for the addition of irinotecan to pre-operative CRT; [49] [50] [51] however, a randomized phase II RTOG trial showed no improvement.
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Given that irinotecan is not active in the adjuvant setting, [53] [54] [55] it will be difficult to envision the practice-changing addition of irinotecan to preoperative CRT regimens based on the results of a single trial. Thus, the chemotherapy backbone for pre-operative CRT remains continuous infusion 5-FU alone or capecitabine.
Need for Radiation Therapy?
Despite the failures of improving on combination chemotherapy plus radiation, an alternative approach to improve pre-operative therapy is to administer modern chemotherapy alone pre-operatively. Several small studies have demonstrated high pCR rates (up to 27 %) using preoperative FOLFOX without the added toxicities of radiation therapy.
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Based on these results, the large randomized phase III PROSPECT trial will test if it is possible to eliminate radiation therapy in patients who have a good response to induction FOLFOX chemotherapy. In this trial, patients will be randomized to a standard therapy arm (pre-operative 5-FU/RT, followed by TME, and then eight cycles of postoperative FOLFOX). In the experimental arm, all patients will undergo six cycles of pre-operative FOLFOX. Patients demonstrating progression or responses <20 % will receive pre-operative 5-FU/RT, followed by TME, and then two more cycles of postoperative FOLFOX. However, patients demonstrating good responses (>20 %) will proceed to TME (without pre-operative RT), and then six cycles of postoperative FOLFOX. The final primary endpoints will be R0 resection rates, time-to-local recurrence, and disease-free survival rates. It will be interesting to see if these selected patients who forego RT will have equivalent outcomes compared to standard therapy⎯but without the added toxicity of RT.
Optimal Timing of Surgery?
Another approach to improve pCR rates has focused on optimizing the timing between pre-operative CRT and surgery. Historically, studies that have looked at longer intervals between pre-operative CRT and surgery demonstrate improved pCR rates, but pelvic fibrosis has been thought to be problematic if resection is delayed beyond 6 to 8 weeks. [58] [59] [60] However, increasing data suggest that a longer interval between radiation and resection may be beneficial. One study showed improved tumor downstaging if surgery was performed 6 to 8 weeks after radiation compared with 2 weeks after radiation. 58 A retrospective analysis also suggested an improvement in pCR rates and a decrease in morbidity when surgery was performed greater than 7 weeks after CRT. 59 There has been concern that a longer interval between CRT and surgery could lead to increased operative morbidity and prolonged hospital stays even despite improved pCR rates. 60 Moreover, some studies have failed to demonstrate an association between an increased interval before surgery and improved pCR rates. 61 meeting from the first 32 patients reported a 33 % pCR rate with over a 90 % treatment compliance rate. 63 The mature study results from both the Timing Trial and the CONTRE trial are eagerly awaited, and will no doubt provide important information for the design and conduct of future neoadjuvant rectal cancer trials.
Need for Surgery in All Rectal Cancer Patients?
The possibility of omission of surgery after successful chemoradiation ('organ preservation') is the most pressing current research question in rectal cancer. With most series showing pCR rates of 15-18 %, and newer series showing pCR rates of over 30 %, there may be a subset of patients who will likely not benefit from resection. Several reports have observed that a subset of patients who receive CRT and achieve a clinical complete response (cCR) can have prolonged disease-free intervals without surgery.
Habr-Gama reported on a group of 265 rectal cancer patients who received pre-operative 5-FU/RT of which 26 % had a cCR. 64 Patients without a cCR Patients that recurred locally were salvaged with resection; although three patients recurred with distant metastatic disease. 67 While all of these studies pose fascinating and important clinical questions, they will need to be confirmed with larger, randomized phase III trials.
Despite the obvious attraction of identifying patients who could undergo nonoperative management of rectal cancer, there remain critical barriers to overcome before such an approach can be widely adopted. One area of uncertainty is the accurate identification of a cCR. Prior studies have
shown discordance between cCR and pCR. 68 Indeed, a complete response in the primary tumor may not be indicative of a complete response in nodal disease. In one series, 7 % of patients with a pCR in the primary tumor had positive nodal disease. 69 This underscores the need for a robust, clear, and precise definition for a cCR. Some investigators have advocated that a cCR can only be documented with a negative full thickness biopsy and normal endoscopic evaluation. 70 However, even such careful approaches can be confounded by operator variability and sampling bias. Other techniques are being investigated to better define a cCR including endorectal ultrasound as well as diffusion-weighted MRI (DW-MRI). A prospective study from 2007 to 2010 showed that DW-MRI can accurately predict pCRs, although not unequivocally in all circumstances. 71 Retrospective studies have also suggested the utility of DW-MRI in assessing pCR. [72] [73] [74] [75] The CARTS study is attempting to define a role for nonradical surgery and incorporates transanal endoscopic microsurgery (TEM) in well-defined patient subsets. 76 More research needs to be carried out to determine the best methods for assessing complete response after neo-adjuvant therapy. 77 Similar trials have been proposed in the US. However, without better prognostic and predictive biomarkers and more accurate clinical assessment of response to therapy, it will be challenging to prospectively identify which patient subgroups would be appropriate candidates for organ preservation. Thus, without better risk-stratification, definitive phase III clinical trials will be a difficult undertaking given the large sample sizes required and the potential reluctance in recruiting patients to an observation arm. Nevertheless, patients frequently express a strong desire to avoid surgery. 66 Therefore, the research community should not be dissuaded in efforts to launch large randomized clinical trials that include an observation arm after a cCR⎯as long as robust basic, translational, and clinical endpoints are mandated. For perspective, it is worth noting that anal cancer, which was once a purely surgical disease, is now routinely managed with CRT. 78 In summary, the integration of multi-modal rectal cancer treatment, improvements in our understanding of the optimal timing of each, and refinements in each mode of therapy have led to substantial improvements in rectal cancer survival. However, there is still much work to be performed to determine the optimal way to integrate these therapies, minimize toxicities, and possibly even provide an organpreservation approach. n
